Nuvation Bio Expands Safusidenib Program with Strong Phase II Data
NEW YORK, July 20, 2026 Nuvation Bio Inc. has announced positive updated Phase II clinical data for safusidenib, its...
glioma
Advertisement
Dizal’s ZEGFROVY Outperforms Chemotherapy in NSCLC
SHANGHAI, China, May 29, 2026 Dizal has announced groundbreaking results from the global Phase 3 WU-KONG28 trial, demonstrating that...
Servier’s VORANIGO® Delivers More Than 44 Months of Progression-Free Survival in IDH-Mutant Glioma
BOSTON, Massachusetts, May 31, 2026 Servier has announced extended follow-up results from the pivotal Phase 3 INDIGO trial, demonstrating...
Nuvation Bio Strengthens Oncology Pipeline with IBTROZI and Safusidenib Advances
New York, USA, April 21,2026 In a major development in global oncology drug innovation, Nuvation Bio Inc. has highlighted...
Telix NDA Accepted for Pixclara Brain Cancer Imaging
Melbourne, Australia & Indianapolis, USA | April 10, 2026 Telix Pharmaceuticals has announced that the U.S. Food and Drug...
Advertisements
TLX101-Px MAA Filed in Europe for Brain Cancer Imaging
MELBOURNE, AUSTRALIA & INDIANAPOLIS, UNITED STATES — February 18, 2026 Telix Pharmaceuticals has submitted a European Marketing Authorization Application...
Advertisement
